This thesis addresses a wide range of cutaneous toxicities associated with anti-PD1 antibodies. These immunotherapies are now commonly utilised for the patients with American Joint Committee on Cancer (AJCC) stage III and IV melanoma. Due to increasing usage of anti-PD1 antibodies, it is paramount for clinicians to be familiar with a range of different side effects. This research project was aimed at identifying and diagnosing the cutaneous toxicities associated with the drug use. Then attempts were made to identify the mechanisms behind the associated cutaneous toxicities, any association to the disease progression, specific immunohistochemistry and histology findings within the cutaneous toxicities, and lastly to explore appropriate treat...
International audienceBackground: Checkpoint inhibitors provide an effective approach for the melano...
Progress in the understanding of many tumors has enabled the development of new therapies, such as t...
BACKGROUND Anti-programmed cell death 1 (PD-1) antibodies represent an effective treatment option...
PURPOSE: Immunotherapy experienced impressive progresses in cancer treatment. Antibodies against PD-...
Background: Anti-programmed cell death (PD)-1 therapy is emerging as the backbone of new standard of...
The discovery of immune checkpoint inhibition (ICI) sparked a revolution in the era of targeted anti...
Background Checkpoint inhibitors have revolutionized advanced melanoma care; however, their cutaneo...
Background: The anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) ...
© 2020 Elsevier Inc. The development of immunotherapy has led to a paradigm shift in the treatment o...
Treatment with fully human monoclonal antibodies against programmed death 1 (PD1) receptor has shown...
Therapies that activate the immune system through blocking the binding of programmed death ligand 1 ...
Immune checkpoint blockers (ICBs) have been widely used during the last decade for the treatment of ...
Background: Checkpoint inhibitors provide an effective approach for the melanoma treatment. They pro...
Immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4 antibodies) are a standard of care for advan...
Immune checkpoint inhibitors (ICIs) have emerged as novel options that are effective in treating var...
International audienceBackground: Checkpoint inhibitors provide an effective approach for the melano...
Progress in the understanding of many tumors has enabled the development of new therapies, such as t...
BACKGROUND Anti-programmed cell death 1 (PD-1) antibodies represent an effective treatment option...
PURPOSE: Immunotherapy experienced impressive progresses in cancer treatment. Antibodies against PD-...
Background: Anti-programmed cell death (PD)-1 therapy is emerging as the backbone of new standard of...
The discovery of immune checkpoint inhibition (ICI) sparked a revolution in the era of targeted anti...
Background Checkpoint inhibitors have revolutionized advanced melanoma care; however, their cutaneo...
Background: The anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) ...
© 2020 Elsevier Inc. The development of immunotherapy has led to a paradigm shift in the treatment o...
Treatment with fully human monoclonal antibodies against programmed death 1 (PD1) receptor has shown...
Therapies that activate the immune system through blocking the binding of programmed death ligand 1 ...
Immune checkpoint blockers (ICBs) have been widely used during the last decade for the treatment of ...
Background: Checkpoint inhibitors provide an effective approach for the melanoma treatment. They pro...
Immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4 antibodies) are a standard of care for advan...
Immune checkpoint inhibitors (ICIs) have emerged as novel options that are effective in treating var...
International audienceBackground: Checkpoint inhibitors provide an effective approach for the melano...
Progress in the understanding of many tumors has enabled the development of new therapies, such as t...
BACKGROUND Anti-programmed cell death 1 (PD-1) antibodies represent an effective treatment option...